中德临床肿瘤学杂志（英文版）2011，Vol.10Issue(8)：472-475,4.DOI:10.1007/s10330-011-0810-y
多西他赛与吉西他滨分别顺泊治疗晚期非小细胞肺癌的临床研究
Clinical observation of docetaxel plus cisplatin versus gemcitabine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer
Yongguang Cai 1Ming Li 1Xin Xie1
作者信息
摘要
Abstract
Objective: The aim of this study was to evaluate the clinical efficacy and side effects of docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment in the patients with advanced non-small-cell lung cancer (NSCLC). Methods: Seventy-six patients with advanced NSCLC who were chemotherapy-naive were enrolled in two groups. In docetaxel group (DP group) the patients received docetaxe175 mg/m2 and cisplatin 60 mg/m2 on day 1. In gemcitabine group (GP group) the patients received gemcitabine 1000 mg/m2 on day 1 and day 8. The dosage of cisplatin was the same as DP group. The two regiments were administrated intravenously every 21 days as a cycle, each patient received 2-4 cycles. All patients were followed up until disease progressed or patients died. Results: The overall response rates were 43.5％ in DP group and 45.9％ in GP group. The response rate was significantly different between the initial treated group and retreated group in both two groups (53.8％ vs 23.0％ in DP group and 56％ vs 25％ in GP group, P ＜ 0.05, respectively). The main side effects were bone marrow suppression and thrombocytopenia. Conclusion: Docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment for the patients with advanced NSCLC were efficient and well-tolerated chemotherapeutic approachs with Iow toxicity levels. The efficacy and major toxicity in two groups were similar.关键词
docetaxel/cisplatin/ gemcitabine/cisplatin/ advanced non-small-cell lung cancer (NSCLC)Key words
docetaxel/cisplatin/ gemcitabine/cisplatin/ advanced non-small-cell lung cancer (NSCLC)引用本文复制引用
Yongguang Cai,Ming Li,Xin Xie..多西他赛与吉西他滨分别顺泊治疗晚期非小细胞肺癌的临床研究[J].中德临床肿瘤学杂志（英文版）,2011,10(8):472-475,4.
